Unlocking the Potential of Abandoned and Expired Patents: A Strategic Guide to Competitive Advantage
Drug patent abandonment is not a clerical failure. It is a calculated move within a broader lifecycle management strategy or […]
The CDMO Strategic Intelligence Playbook: 10 High-Value Services That Separate Winning Drug Programs from the Rest
The contract development and manufacturing organization industry crossed $238 billion in global market value in 2024. By 2032, analysts project
The Persistent Problem: Why Hospitals Keep Running Out of Generic Drugs
The U.S. generic drug market saves $445 billion a year. It also fails, systematically and predictably, to keep the most
The Persistent Problem: Why Hospitals Keep Running Out of Generic Drugs Read Post »
Generic Drug Regulatory Strategy: The Complete Playbook for Pharma IP Teams
1. What a Generic Drug Actually Is, Legally and Commercially The Regulatory Definition and Why It Is a Legal Construct,
Generic Drug Regulatory Strategy: The Complete Playbook for Pharma IP Teams Read Post »
Why Google Patents Fails Drug Patent Searches — And What to Use Instead
A field-by-field breakdown of 15 structural flaws that put pharmaceutical IP strategy at risk There is a particular kind of
Why Google Patents Fails Drug Patent Searches — And What to Use Instead Read Post »
Drug Patent Filing in Emerging Markets: The Complete IP Strategy Guide for Pharma Decision-Makers
The emerging market pharmaceutical story has a simple headline: $500 billion by 2027, compounding at roughly 6.9% annually. What that
Biosimilar Analytical Similarity Assessments: The Complete Regulatory, IP, and Investment Playbook
Part 1: The Market Reality Behind Analytical Similarity The Patent Cliff Driving a $185 Billion Opportunity The global biosimilar market
Navigating the Collision of Pharmaceutical Innovation and Managed Care Economics
A deep-dive for pharma/biotech IP counsel, formulary directors, health economics leads, and institutional investors The Scale of the Problem: Spending
Navigating the Collision of Pharmaceutical Innovation and Managed Care Economics Read Post »
Biosimilars vs. Biologics: The Complete Pipeline Strategy Guide for IP Teams and Portfolio Managers
A technical deep-dive into how biosimilar competition is reshaping R&D investment, patent strategy, and lifecycle management across the biopharmaceutical industry.
